{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"submitter":["Hernandez S"],"pubmed_abstract":["<i>CYP3A5</i> genetic variants are associated with tacrolimus metabolism. Controversy remains on whether <i>CYP3A4</i> increased [* <i>1B</i> (rs2740574), <i>*1G</i> (rs2242480)] and decreased function [*22 (rs35599367)] genetic variants provide additional information. This study aims to address whether tacrolimus dose-adjusted trough concentrations differ between combined CYP3A (CYP3A5 and CYP3A4) phenotype groups. Significant differences between CYP3A phenotype groups in tacrolimus dose-adjusted trough concentrations were found in the early postoperative period and continued to 6 months post-transplant. In CYP3A5 nonexpressers, carriers of CYP3A4*7Bor *7G variants (Group 3) compared to <i>CYP3A4*1/*1</i> (Group 2) patients were found to have lower tacrolimus dose-adjusted trough concentrations at 2 months. In addition, significant differences were found among CYP3A phenotype groups in the dose at discharge and time to therapeutic range while time in therapeutic range was not significantly different. A combined CYP3A phenotype interpretation may provide more nuanced genotype-guided TAC dosing in heart transplant recipients."],"journal":["Research square"],"pagination":["rs.3.rs-2921796"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC10246090"],"repository":["biostudies-literature"],"pubmed_title":["Composite CYP3A (CYP3A4 and CYP3A5) phenotypes and influences on tacrolimus dose adjusted concentration in adult heart transplant recipients."],"pmcid":["PMC10246090"],"pubmed_authors":["Aquilante C","Van Driest S","Lindenfeld J","Liu M","Deininger K","Hernandez S","Schlendorf K"],"additional_accession":[]},"is_claimable":false,"name":"Composite CYP3A (CYP3A4 and CYP3A5) phenotypes and influences on tacrolimus dose adjusted concentration in adult heart transplant recipients.","description":"<i>CYP3A5</i> genetic variants are associated with tacrolimus metabolism. Controversy remains on whether <i>CYP3A4</i> increased [* <i>1B</i> (rs2740574), <i>*1G</i> (rs2242480)] and decreased function [*22 (rs35599367)] genetic variants provide additional information. This study aims to address whether tacrolimus dose-adjusted trough concentrations differ between combined CYP3A (CYP3A5 and CYP3A4) phenotype groups. Significant differences between CYP3A phenotype groups in tacrolimus dose-adjusted trough concentrations were found in the early postoperative period and continued to 6 months post-transplant. In CYP3A5 nonexpressers, carriers of CYP3A4*7Bor *7G variants (Group 3) compared to <i>CYP3A4*1/*1</i> (Group 2) patients were found to have lower tacrolimus dose-adjusted trough concentrations at 2 months. In addition, significant differences were found among CYP3A phenotype groups in the dose at discharge and time to therapeutic range while time in therapeutic range was not significantly different. A combined CYP3A phenotype interpretation may provide more nuanced genotype-guided TAC dosing in heart transplant recipients.","dates":{"release":"2023-01-01T00:00:00Z","publication":"2023 May","modification":"2025-04-04T10:21:50.072Z","creation":"2025-02-19T02:38:03.721Z"},"accession":"S-EPMC10246090","cross_references":{"pubmed":["37292893"],"doi":["10.21203/rs.3.rs-2921796/v1"]}}